INTRODUCTION
============

Thromboembolism is a major complication of stent-assisted coiling for the treatment of a cerebral aneurysm \[[@b1-neuroint-2018-01088]\]. Clopidogrel (Bristol-Myers Squibb, New York, NY, USA) has been used with aspirin (Bayer, Leverkusen, Germany) for stent-assisted coiling in the treatment of cerebral aneurysms. However, the cytochrome P450 (CYP) 2C19 polymorphism associated with clopidogrel resistance is so common that it appears in more than 55% of East Asian populations \[[@b2-neuroint-2018-01088]\]. Among homozygous alleles of clopidogrel resistance caused by the loss of function of CYP2C19, clopidogrel cannot inhibit the activity of platelets even after loading an additional dose \[[@b3-neuroint-2018-01088]\]. Prasugrel (Eli Lilly, Indianapolis, IN, USA) is a third-generation orally-active P2Y12 inhibitor that is also converted to an active metabolite by the CYP system \[[@b4-neuroint-2018-01088]\]. It is more effective than clopidogrel in its rapid onset of efficacy and potent inhibitory effect on platelet aggregation. There have been studies using prasugrel in the treatment of cerebral aneurysms with stent-assisted coils, but no studies have been performed on only patients with clopidogrel resistance \[[@b5-neuroint-2018-01088]-[@b8-neuroint-2018-01088]\]. In addition, there is no definite guideline for patients with low-body weight, as in Koreans for whom prasugrel was not allowed, probably due to the risk of bleeding. Thus, we aimed to investigate changes in the value of P2Y12 resistance unit (PRU) when prasugrel was administered to patients with clopidogrel resistance.

MATERIALS AND METHODS
=====================

In the treatment of an intracranial aneurysm, from 6 days before the procedure, 100 mg of aspirin and 75 mg of clopidogrel were administered for 5 days. Aspirin reaction unit and PRU were examined at 11:00 A.M. the day before the procedure using the VerifyNow assay (Accumetrics, San Diego, CA, USA). PRU and percentage inhibition values were measured to evaluate platelet reactivity. The reactivity of platelet function to P2Y12 inhibitors was divided into three categories: "non-responder" (less than 10%), "hypo-responder" (10--20%), and responder (over 20%) \[[@b9-neuroint-2018-01088]\]. The resistance to clopidogrel was defined as an inhibition of PRU less than 20%. In this case, PRU was re-examined at 8:00 A.M. on the day of the procedure using 5 mg as a maintenance dose after loading 20 mg of prasugrel from the day before the procedure. Patients with a history of transient ischemic attack (TIA) or ischemic stroke were excluded \[[@b10-neuroint-2018-01088]\]. We also collected information pertaining to patient demographics including height and body weight, risk factors, past medical history, and laboratory findings. Clinical follow-up was made after the embolization procedure.

RESULTS
=======

We treated 98 consecutive patients with an aneurysm between January 2018 and July 2018, and 24 patients (24.5%) had resistance to clopidogrel. The median age was 61 years, and 19 patients (79.1%) were female ([Table 1](#t1-neuroint-2018-01088){ref-type="table"}). The median body weight and body mass index was 50.5 kg and 23.8 kg/m^2^, respectively. All aneurysms were unruptured. Four patients had two or more aneurysms. Thirteen patients (54.2%) had small (3--5 mm) aneurysms, and all aneurysms were confined to the anterior circulation. Intracranial stents were used in 18 patients (75.0%). The mean PRU value at admission was 238.5±36.9, and the percentage inhibition value was 4.8±6.3%. Thirteen patients (54.2%) had a percentage inhibition value of 0%. After the use of prasugrel, the mean PRU and percentage inhibition values were measured as 124.9±49.9 and 48.0±19.24, respectively. All patients except one patient had a PRU inhibition value as a responder. There was no hemorrhage or thromboembolic complication during a mean follow-up of 1.5 months (range, 1--7) after the embolization procedure.

DISCUSSION
==========

When prasugrel was administered in patients with resistance to clopidorel, the percentage inhibition values of PRU were within the effective range for most patients (95.8%). Only two of these patients had a percentage inhibition value of more than 70 in PRU, and both were over 60 kg. In addition, even those with relatively low-body weights were found to have reached the effective range when low doses of prasugrel were given.

The most frequently reported genetic polymorphism in the use of clopidogrel is increased mortality from myocardial infarction, stroke, and vascular disease, and it is particularly likely to cause thrombosis after stenting \[[@b2-neuroint-2018-01088]\]. In comparison, prasugrel has a fast and potent antiplatelet effect; it also maintains an almost 80% platelet inhibitory effect at 2 hours after administration and maintains its effect continuously \[[@b4-neuroint-2018-01088]\]. However, the use of prasugrel for cerebrovascular disease is still debated, as it involves the problem of intracranial bleeding \[[@b11-neuroint-2018-01088]\]. Since prasugrel has been used for acute myocardial infarction, it also has indications for stent-assisted coiling for reimbursement from the Korean Ministry of Food and Drug Safety \[[@b12-neuroint-2018-01088]\].

Unlike Westerners, however, Asians are known to weigh less and have a higher incidence of cerebral hemorrhage \[[@b13-neuroint-2018-01088]\]. In fact, only 14% of the participants in the TRITRON-TIMI 38 study who have proven to have hemorrhagic complications from prasugrel were from the Middle East, Africa, or Asia-Pacific region, suggesting that it is difficult to generalize to Asian people \[[@b10-neuroint-2018-01088]\]. In fact, there was no difference in bleeding complications with clopidogrel in randomized controlled trial for acute coronary syndrome in Japan where a low dose of prasugrel (20/3.75 mg, loading/maintenance dose) was used \[[@b14-neuroint-2018-01088]\].

In contrast to acute coronary syndrome, stent-assisted coiling is not generally required for lifelong therapy of antiplatelet agents, so low-dose prasugrel for short-term use may be effective. However, as reported in previous large-scale studies, it is advisable to consider reducing the dose for patients older than 75 years or for patients weighing less than 60 kg and avoiding use in patients with a history of stroke or TIA \[[@b10-neuroint-2018-01088]\]. It should be noted, however, that in other studies, the value of PRU itself was used instead of percentage inhibition values, unlike in our study, because PRU values were considered more important \[[@b15-neuroint-2018-01088]\].

Our study has some limitations. This study was a single-arm retrospective study, and no long-term follow-up was performed. Also, it is difficult to investigate an independent predictor because there were a small number of participants.

In conclusion, in patients resistant to clopidogrel, low-dose prasugrel seems to be effective in keeping the percentage inhibition value of PRU within the normal range in treatment of a cerebral aneurysm. Further study will be needed to determine the optimal dose of prasugrel to enhance the prevention effect against thromboembolism and to reduce hemorrhagic complications during stent-assisted coiling.
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Characteristics of patients treated with prasugrel

                                                               Value (n=24)
  ------------------------------------------------------------ ------------------
  Age (years)                                                  61.0 (54.5-66.8)
  Female sex                                                   19 (79.1)
  Body weight (kg)                                             57.7 (56.1-62.5)
  Body mass index (kg/m^2^)                                    23.8 (22.6-25.3)
  Hypertension                                                 9 (37.5)
  Diabetes                                                     4 (16.7)
  Hyperlipidemia                                               5 (20.8)
  Previous use of antiplatelet agent                           2 (8.3)
  ARU                                                          453.5±72.9
  PRU (initial)                                                238.5±36.9
  Percentage inhibition (initial)                              4.8±6.25
   Non-responder (initial)                                     17 (70.8)
   Hypo-responder (initial)                                    7 (29.2)
   Responder (initial)                                         0
  PRU (after use of prasugrel)                                 124.9±49.9
  Percentage inhibition (after use of prasugrel)               48.0±19.24
   Non-responder (after)                                       1 (4.2)
   Hypo-responder (after)                                      0
   Responder (after)                                           24 (95.8)
  Multiple aneurysms in procedure                              4 (16.7)
  Use of stent                                                 18 (75.0)
   Neuroform atlas (Stryker Neurovascular, Fremont, CA, USA)   17 (94.4)
   LVIS blue (MicroVention,Tustin, CA, USA)                    1 (5.6)

Values are presented as mean±standard deviation, medians (with quartiles), or number (%).

ARU, aspirin reaction unit; PRU, P2Y12 reaction unit.
